JP2018502860A5 - - Google Patents

Info

Publication number

JP2018502860A5

JP2018502860A5 JP2017536526A JP2017536526A JP2018502860A5 JP 2018502860 A5 JP2018502860 A5 JP 2018502860A5 JP 2017536526 A JP2017536526 A JP 2017536526A JP 2017536526 A JP2017536526 A JP 2017536526A JP 2018502860 A5 JP2018502860 A5 JP 2018502860A5

Authority

JP

Japan

Prior art keywords

polypeptide

seq

amino acid

acid sequence

pharmaceutical formulation

Prior art date

2016-01-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 72
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 67
• 229920001184 polypeptide Polymers 0.000 claims description 66
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
• 239000000825 pharmaceutical preparation Substances 0.000 claims description 38
• 239000008194 pharmaceutical composition Substances 0.000 claims description 34
• 229920000642 polymer Polymers 0.000 claims description 20
• 238000000034 method Methods 0.000 claims description 17
• 230000001225 therapeutic effect Effects 0.000 claims description 16
• 229920002125 Sokalan® Polymers 0.000 claims description 10
• 239000000203 mixture Substances 0.000 claims description 10
• 239000007787 solid Substances 0.000 claims description 8
• HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 7
• HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 7
• HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 7
• 229940112141 dry powder inhaler Drugs 0.000 claims description 6
• HEBDGRTWECSNNT-UHFFFAOYSA-N 2-methylidenepentanoic acid Chemical compound CCCC(=C)C(O)=O HEBDGRTWECSNNT-UHFFFAOYSA-N 0.000 claims description 5
• 125000000129 anionic group Chemical group 0.000 claims description 5
• 206010020718 hyperplasia Diseases 0.000 claims description 4
• 238000007911 parenteral administration Methods 0.000 claims description 4
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
• 230000003834 intracellular effect Effects 0.000 claims description 3
• 239000006199 nebulizer Substances 0.000 claims description 3
• 230000001766 physiological effect Effects 0.000 claims description 3
• 239000002504 physiological saline solution Substances 0.000 claims description 3
• 238000001694 spray drying Methods 0.000 claims description 3
• 230000002792 vascular Effects 0.000 claims description 3
• 239000011780 sodium chloride Substances 0.000 claims description 2
• 238000009472 formulation Methods 0.000 claims 7
• 238000001035 drying Methods 0.000 claims 5
• 238000011200 topical administration Methods 0.000 claims 3
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 230000002906 microbiologic effect Effects 0.000 claims 2
• 239000000126 substance Substances 0.000 claims 2
• 230000002110 toxicologic effect Effects 0.000 claims 2
• 231100000027 toxicology Toxicity 0.000 claims 2
• 230000003139 buffering effect Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 235000011187 glycerol Nutrition 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 238000003860 storage Methods 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 description 8
• 108090000623 proteins and genes Proteins 0.000 description 8
• 230000026683 transduction Effects 0.000 description 8
• 238000010361 transduction Methods 0.000 description 8
• 230000004927 fusion Effects 0.000 description 5
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
• 238000012986 modification Methods 0.000 description 3
• 230000004048 modification Effects 0.000 description 3
• NXUWTKIOMJSLSV-DEEZXRHXSA-N (2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]hexanoyl]amino]propanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@@H](N)Cc1ccc(O)cc1)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O NXUWTKIOMJSLSV-DEEZXRHXSA-N 0.000 description 2
• 208000029523 Interstitial Lung disease Diseases 0.000 description 2
• 108010083015 MMI-0100 Proteins 0.000 description 2
• 210000004204 blood vessel Anatomy 0.000 description 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000002401 inhibitory effect Effects 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 208000032544 Cicatrix Diseases 0.000 description 1
• 206010028980 Neoplasm Diseases 0.000 description 1
• 208000035269 cancer or benign tumor Diseases 0.000 description 1
• 210000004027 cell Anatomy 0.000 description 1
• 210000004351 coronary vessel Anatomy 0.000 description 1
• 201000010099 disease Diseases 0.000 description 1
• 208000035475 disorder Diseases 0.000 description 1
• 238000010494 dissociation reaction Methods 0.000 description 1
• 230000005593 dissociations Effects 0.000 description 1
• 239000010419 fine particle Substances 0.000 description 1
• 238000000338 in vitro Methods 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 230000001613 neoplastic effect Effects 0.000 description 1
• 230000014511 neuron projection development Effects 0.000 description 1
• 238000004321 preservation Methods 0.000 description 1
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
• 238000011084 recovery Methods 0.000 description 1
• 231100000241 scar Toxicity 0.000 description 1
• 230000037387 scars Effects 0.000 description 1